- In April 2022, ProImmune Ltd. introduced a B-cell ELISpot assay service, designed to evaluate the immune response of B cells, which are vital for the body's defense against infections. This assay enables researchers to measure the effectiveness of vaccines and therapeutic drugs by quantifying the number of B cells that produce specific antibodies in response to stimuli. As a result, it provides valuable insights into vaccine efficacy and drug potency
- In June 2022, BD partnered with CerTest Biotec to develop a molecular diagnostic test for the Monkeypox virus, which is closely related to smallpox. This collaboration aims to enhance the diagnosis and management of Monkeypox infections by utilizing the BD MAX™ open system reagent suite to validate the CerTest VIASURE Monkeypox CE/IVD molecular test. The assay will be accessible to BD MAX™ users and is expected to contribute to a better understanding of the disease's global spread
- In March 2021, PerkinElmer announced the successful completion of its acquisition of Oxford Immunotec for a total of USD 590.9 million. This strategic move is expected to enhance PerkinElmer's automation capabilities and expand the accessibility of tuberculosis testing to a broader customer base. The acquisition positions the company to improve its offerings in the diagnostic market significantly
- In September 2022, Sweden-based Mabtech introduced ELISpot kits in a 100-plate format, featuring pre-coated plates to save time and reduce assay variability. Additionally, in 2022, the company expanded its FluoroSpot Flex platform by offering the Human IL-21 analyte in two colors. These advancements aim to streamline research processes and enhance flexibility for immunological assays
- In June 2021, U.S.-based Cellular Technology Limited (CTL) introduced ImmunoSpot kits, featuring pre-coating quality-controlled (PCQC) plates. These plates provide an essential audit trail for ELISPOT analysis, enhancing the reliability and traceability of the assay. The launch aimed to improve quality control and streamline the ELISPOT process for researchers
Frequently Asked Questions
The market is segmented based on Global FluoroSpot Market Segmentation, By Product (Assay Kits, Analyzers, and Ancillary Products), Application (Diagnostic Applications, Research Applications, Cancer Research, Drug Discovery, and Disease Diagnosis), End User (Hospitals and Clinical Laboratories, Biopharmaceutical Companies, and Research Institute) – Industry Trends and Forecast to 2031
.
The Global Fluorospot Market size was valued at USD 292.20 USD Million in 2023.
The Global Fluorospot Market is projected to grow at a CAGR of 15% during the forecast period of 2024 to 2031.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..
